1. GPCR/G Protein
  2. Leukotriene Receptor
  3. Montelukast

Montelukast (Synonyms: MK0476 free base)

Cat. No.: HY-13315A
Handling Instructions

Montelukast is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT1). Montelukast can be used for the reseach of asthma and liver injury. Montelukast also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage.

For research use only. We do not sell to patients.

Montelukast Chemical Structure

Montelukast Chemical Structure

CAS No. : 158966-92-8

Size Stock
100 mg   Get quote  
250 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Other In-stock Forms of Montelukast:

Other Forms of Montelukast:

Top Publications Citing Use of Products

Publications Citing Use of MCE Montelukast

View All Leukotriene Receptor Isoform Specific Products:

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Montelukast is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT1). Montelukast can be used for the reseach of asthma and liver injury. Montelukast also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage[1].

IC50 & Target[1]

CysLT1

 

In Vitro

Montelukast (5 μM; 1 h) inhibits APAP-induced cell damage[1].

In Vivo

Montelukast (3 mg/kg; oral gavage) protects against APAP-induced hepatotoxicity in mice[1].
Montelukast (1 mg/kg; miniosmotic pump administration) reduces the airway remodeling changes observed in OVA-treated mice and blocks the actions of cysteinyl leukotrienes (LT) C4, D4, and E4 mediated by the CysLT1 receptor[2].
Montelukast (1 mg/kg; miniosmotic pump administration) reduces the elevated levels of IL-4 and IL-13 found in the BAL fluid of OVA-treated mice[2].

Animal Model: C57BL/6J mice (8-week-old; 22-25 g) are induced acute hepatic injury[1]
Dosage: 3 mg/kg
Administration: Oral gavage 1 h after saline or APAP administration
Result: Decreased serum levels of alanine transaminase (ALT) and aspartate aminotransferase (AST), and alleviated liver damage.
Molecular Weight

586.18

Formula

C₃₅H₃₆ClNO₃S

CAS No.

158966-92-8

SMILES

O=C(O)CC1(CS[[email protected]@H](C2=CC=CC(/C=C/C3=NC4=CC(Cl)=CC=C4C=C3)=C2)CCC5=CC=CC=C5C(C)(O)C)CC1

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Keywords:

MontelukastMK0476MK 0476MK-0476Leukotriene ReceptorcysteinylleukotrieneCysltr1asthmaliverinjuryantioxidantintestinalischemia–reperfusionicardiacdamageInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email address *

Phone number *

 

Organization name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Montelukast
Cat. No.:
HY-13315A
Quantity:
MCE Japan Authorized Agent: